Led by new investor Gilde Healthcare , the financing round also drew participation from existing investors , including Kurma Partners ; Ysios Capital ; Idinvest Partners ; Boehringer Ingelheim Venture...
The company concludes a 2.2 million Euro round led by ”la Caixa” through Caixa Capital Risc. Also participating in the operation were Ysios Capital, which led the first investment round for the co...
Ysios Capital and Caixa Capital Risc are two of the 25 life sciences investment funds currently operating in the BioRegion of Catalonia. These two funds, Ysios Capital and Caixa Capital Risc, often jo...
RCD cuenta con amplia experiencia y conocimiento en el asesoramiento a instituciones públicas de investigación y a compañías biotecnológicas, a las que presta un servicio integral en aspectos com...
The proceeds will support the development of the HTI immunogen as a therapeutic vaccine against HIV infection, up to the completion of a Phase 2 proof-of-concept efficacy trial in HIV-infected individ...
Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...
En España se están consolidando un número reducido de inversores de capital riesgo especializados en biotecnología. Algunos de ellos están recibiendo el apoyo de inversores internacionales y otro...
“El fondo está orientado a empresas altamente innovadoras, en los campos de productos terapéuticos, diagnóstico y dispositivos médicos para necesidades claramente no cubiertas”, apunta Joël J...